Mountain Crest Acquisition Corp. II. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/29/2021 | $19.00 | Buy | Lake Street |
Trading to commence on Nasdaq on Oct. 29, 2021, under the ticker symbol BTTX Better Therapeutics, Inc., a prescription digital therapeutics (PDT) company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the completion of its business combination with Mountain Crest Acquisition Corp II (NASDAQ:MCAD, "Mountain Crest II"))), a publicly traded special purpose acquisition corporation or SPAC. The resulting combined company will commence trading its shares on Nasdaq under the ticker symbol "BTTX" on October 29, 2021. The shareholders of Mountain Crest Acquisition Corp II approved the transaction at a special meeting held on October
NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ:MCAD) (the "Company"), a publicly traded special purpose acquisition company, announced today that in a special meeting of stockholders on October 27, 2021, its stockholders voted to approve its proposed business combination (the "business combination") with Better Therapeutics Inc. ("Better Therapeutics"), a company engaged in developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The business combination is expected to close on October 28, 2021, subject to the satisfaction of certain customary closing conditions. As part of the consummation o
NEW YORK and SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ:MCAD, "Mountain Crest II"))), a publicly-traded special purpose acquisition company and Better Therapeutics, Inc. ("Better Therapeutics"), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that MCAD's registration statement on Form S-4 (File No. 333-255493) relating to the previously announced merger of MCAD and Better Therapeutics has been declared effective by the U.S. Securities and Exchange Commission as of October 12, 2021. MCAD also announced that it will hold its special m
Better Therapeutics, Inc. ("Better Therapeutics"), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, has been invited to present at the Lake Street's 5th Annual Best Ideas Growth (BIG5) Conference, which is being held virtually on September 14-15, 2021. To receive additional information, request an invitation or to schedule a one-on-one meeting, please contact your Lake Street representative. About the BIG Conference Lake Street will host its fifth annual BIG (Best Ideas Growth) institutional investor conference showcasing many interesting, dynamic public growth companies. Executives from over 10
Pivotal trial of BT-001 in type 2 diabetes expected to be fully enrolled in Q4 2021, with primary endpoint readout in Q1 2022; de novo submission to FDA requesting marketing authorization planned following completion of trial Clinical development of BT-002 and BT-003 in hypertension and hyperlipidemia on track; pivotal studies expected to commence in 2022 Early clinical discovery in non-alcoholic fatty liver disease (NAFLD) expected to enroll first patient in Q1 2022 Real-world evidence study evaluating the long-term effectiveness and healthcare cost impact of BT-001 to enroll first patient in Q4 2021; two study partners (Colorado Prevention Center and Catalyst Health Network) announced
Provides up to $150 million in total financing in combination with proceeds from previously announced SPAC merger and PIPE investment Funds to support advancement of clinical pipeline and commercialization of first prescription digital therapeutic (PDT) for treating type 2 diabetes Better Therapeutics, Inc. ("Better Therapeutics"), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced it has secured a loan facility for up to $50 million from Hercules Capital, Inc. (NYSE:HTGC). "This transaction comes on the heels of an eventful few months, including the announcement of our pending SPAC m
Open-label, real-world study will evaluate BT-001's cognitive behavioral therapy approach to change behaviors at the root cause of type 2 diabetes Study to evaluate the durability of treatment effect and healthcare utilization changes associated with BT-001 in Catalyst's community-based, clinically integrated, primary care setting Better Therapeutics, Inc. ("Better Therapeutics"), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Catalyst Health Network ("Catalyst"), today announced the commencement of a real-world evidence study to evaluate the long-term effectiveness and healthc
Better Therapeutics, Inc. ("Better Therapeutics"), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is participating in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021. Better Therapeutics' CEO, Kevin Appelbaum, Chief Medical Officer, Mark Berman, M.D., and Interim Chief Financial Officer, Mark Heinen, will provide an overview of Better Therapeutics and its pending merger with Mountain Crest Acquisition Corp. II, a special purpose acquisition company or "SPAC", at 1:00 p.m. ET on Thursday, August 12. About Better Therapeutics Better Therapeutics is a
Open-label, randomized, controlled study will evaluate BT-001's cognitive behavioral therapy approach to change behaviors at the root cause of type 2 diabetes Study to evaluate the durability of treatment effect and healthcare utilization changes associated with BT-001 in a diverse, real-world clinical setting Better Therapeutics, Inc. ("Better Therapeutics"), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Colorado Prevention Center (CPC) Clinical Research, affiliated with the University of Colorado Anschutz Medical Campus, today announced the commencement of a real-world evide
Better Therapeutics, Inc. ("Better Therapeutics"), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is scheduled to participate in two virtual panel discussions at the Cowen 6th Annual FutureHealth Conference on June 17, 2021. Better Therapeutics' Head of Behavioral Medicine, Prapti Mehta, M.D., to participate in session titled "Cognitive Behavioral Therapy (CBT) & Its Use In Digital Therapeutics" at 10:55 a.m. ET on Thursday, June 17. Better Therapeutics' Co-founder and Chief Executive Officer, Kevin Appelbaum, to participate in session titled "Commercialization Of Digital
3 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
3 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
4 - Better Therapeutics, Inc. (0001832415) (Issuer)
3 - Better Therapeutics, Inc. (0001832415) (Issuer)
3 - Better Therapeutics, Inc. (0001832415) (Issuer)
3 - Better Therapeutics, Inc. (0001832415) (Issuer)
SC 13D - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13D - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13G - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13G/A - Better Therapeutics, Inc. (0001832415) (Subject)
SC 13G - Mountain Crest Acquisition Corp II (0001832415) (Subject)
SC 13G - Mountain Crest Acquisition Corp II (0001832415) (Subject)
SC 13G - Mountain Crest Acquisition Corp II (0001832415) (Subject)
Better Therapeutics, Inc., a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Dr. Risa Lavizzo-Mourey to its board of directors; she will also serve as Compensation Committee chair. "Dr. Lavizzo-Mourey brings critical insights into health policy, as well as her background as a primary care physician at a critical juncture for Better Therapeutics," said David Perry, co-founder and chairman of Better Therapeutics. "Her experience and counsel will help us establish our prescription digital therapeutics as the new standard of care for people with cardiometabolic diseases.
8-K - Better Therapeutics, Inc. (0001832415) (Filer)
25-NSE - Mountain Crest Acquisition Corp II (0001832415) (Subject)
425 - Mountain Crest Acquisition Corp II (0001832415) (Subject)
8-K - Mountain Crest Acquisition Corp II (0001832415) (Filer)
425 - Mountain Crest Acquisition Corp II (0001832415) (Subject)
425 - Mountain Crest Acquisition Corp II (0001832415) (Subject)
EFFECT - Mountain Crest Acquisition Corp II (0001832415) (Filer)
424B3 - Mountain Crest Acquisition Corp II (0001832415) (Filer)
S-4/A - Mountain Crest Acquisition Corp II (0001832415) (Filer)
8-K - Mountain Crest Acquisition Corp II (0001832415) (Filer)
Lake Street initiated coverage of Mountain Crest Acquisition Corp. II with a rating of Buy and set a new price target of $19.00